Overview

Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

Status:
Completed

Trial end date:
2019-12-23

Target enrollment:

Participant gender:

Summary

This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.

Phase:

Phase 1

Details

Lead Sponsor:

Allergan

Treatments:

Antibodies, Monoclonal
Erenumab